The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis.
 
Giuseppe Curigliano
Leadership - ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Eva Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
David Proudman
No Relationships to Disclose
 
Dave Nellesen
No Relationships to Disclose
 
Priscilla Lopez
No Relationships to Disclose
 
Samantha Kaufhold
No Relationships to Disclose
 
Olivia Shane
No Relationships to Disclose
 
Adrienne Kwok
No Relationships to Disclose
 
Vaidyanathan Ganapathy
No Relationships to Disclose
 
Adaeze Q. Amefule
Employment - Novartis
 
Agnes Lteif
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Erika P. Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)